Vaxess' flu vaccine patch passes early clinical test, clearing path for further development

Vaxess Technologies has generated early clinical evidence in support of its delivery patch, linking the device to seroprotection rates of over 90% when used to administer an influenza vaccine in a phase 1 trial.